The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
about
The impact of biological interventions for ulcerative colitis on health-related quality of lifeThe impact of biological interventions for ulcerative colitis on health-related quality of lifeThe impact of medical interventions for ulcerative colitis on health-related quality of lifeInterventions and targets aimed at improving quality in inflammatory bowel disease ambulatory careBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInfliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysisAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisRandomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patientsDifferent therapeutic approaches on quality of life in patients with inflammatory bowel disease.A new look at a mainstay ulcerative colitis therapyThe impact of biologics on health-related quality of life in patients with inflammatory bowel disease.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Intestinal anti-inflammatory activity of Sasa quelpaertensis leaf extract by suppressing lipopolysaccharide-stimulated inflammatory mediators in intestinal epithelial Caco-2 cells co-cultured with RAW 264.7 macrophage cells.Pros and cons of medical management of ulcerative colitis.The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamineA systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research.Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT).Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitisEffect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice.Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.A Picrorhiza kurroa derivative, picroliv, attenuates the development of dextran-sulfate-sodium-induced colitis in miceInflammatory bowel disease: a Canadian burden of illness reviewNilotinib-mediated mucosal healing in a rat model of colitis.Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.Therapeutic options in acute severe ulcerative colitis.Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trialDisease activity, quality of life, and indirect costs of ulcerative colitis in PolandEfficacy and safety of drugs for ulcerative colitis.Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis.Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts.Health-related quality of life in pediatric ulcerative colitis patients on conventional medical treatment compared to those after restorative proctocolectomy.The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy.European evidence based consensus for endoscopy in inflammatory bowel disease.Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.Psychometric validation of the SF-36(®) Health Survey in ulcerative colitis: results from a systematic literature review.Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.
P2860
Q24187078-C955A7FB-825C-4896-A53F-F2B14C64F6B6Q24202509-DC939768-B767-4525-B68C-9EF843982300Q24235864-B3F70E34-4D96-4D63-870F-E0115831EED3Q26823569-340E0E64-DC33-4333-8D3F-720090D45B3AQ26999078-3A12605A-847A-48B5-A875-06F2E7E0992EQ27006683-BB5F9EA4-AB0C-45CA-B6E0-249910A905CBQ28079322-BD5B9C81-2CC3-479F-9CF3-B21640E87886Q28657925-53B2B355-C14B-45B3-85B0-A96EA86EC367Q33536129-A49D9E7B-BEA7-4B2C-AD7C-35F47739885DQ34739436-896D2C26-95DC-4E0E-92DA-CF10D6A62EB8Q34940520-96F14BF1-57DA-4EBF-88AC-226F2842751DQ35026298-8960AD92-6368-410A-8B7F-2F719731D7CAQ35026302-FBE8C91A-B299-42BA-905F-10289E03CA43Q35050407-00C2727A-4734-4D5A-9D5F-308D99903153Q35100726-0E0EE6D6-F836-4960-AC64-6BD32DABD4DFQ35148270-E3845CE1-FC0E-46CE-92F3-0F210437080BQ35169255-EE9F6DB2-60BF-440D-B074-FF00EDFBF178Q35230757-26625FB0-BDAA-430F-BE33-1A1581333C7FQ35542672-927BFC94-744E-4008-AF3F-7637AF66C8F4Q35692276-72CBDB06-F886-4708-A371-E10F4EE55858Q36095921-D1259C15-624C-478F-BB53-D6133DBDA8E2Q36344230-FE1EF8E2-4443-4C58-82AD-D463EDA7D413Q36391797-70EF6EB3-BEEF-4312-8F02-C629624491F7Q37208138-145A96C2-16E1-40B8-BE88-8D826A671E39Q37322514-1EAAD00B-C84B-4BF9-9B7E-8CFDD1227B7EQ37345935-7892336C-8446-417D-B441-5FA3DB71A3CAQ37414620-A68595B5-AF09-4BFE-BDE0-B48056334CFEQ37492480-B3D4659C-100D-4CDB-9770-1E722EA829B9Q37561775-D960440E-EB9F-41D2-874D-0640E8ABDD5BQ37714391-E67B78F6-BD96-4A7E-ABD7-DB69616E8EB7Q37727232-EBFF02B9-2731-4734-BD53-B27CCC1E862EQ37812046-36ACF508-18F7-4AD3-B1C4-65F287A2F000Q37892444-AE5E8B74-AA8B-4782-AAA9-C1687875AE9BQ37906501-18DA3EA4-CF13-477E-B032-F88288F57D67Q38036920-8725C6FC-605A-468D-B618-786398BC41D1Q38121000-A0136AF7-ED06-4086-9C95-F8CCC82EBF7AQ38159096-FF984A40-E4E3-4424-A96C-2DFBEF301354Q38184706-1D466478-6075-4FDD-BCBC-81EB611351D7Q38604435-DE5045BC-839D-4A58-AF78-85479956B840Q38694153-C19FBF07-1367-43FF-9B9C-4256AC06E9AC
P2860
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The effects of infliximab ther ...... n ulcerative colitis patients.
@en
The effects of infliximab ther ...... n ulcerative colitis patients.
@nl
type
label
The effects of infliximab ther ...... n ulcerative colitis patients.
@en
The effects of infliximab ther ...... n ulcerative colitis patients.
@nl
prefLabel
The effects of infliximab ther ...... n ulcerative colitis patients.
@en
The effects of infliximab ther ...... n ulcerative colitis patients.
@nl
P2093
P2860
P50
P1476
The effects of infliximab ther ...... n ulcerative colitis patients.
@en
P2093
Allan Olson
Debra Eisenberg
Jewel Johanns
Mohan Bala
Songkai Yan
Stephen B Hanauer
Walter Reinisch
P2860
P304
P356
10.1111/J.1572-0241.2007.01094.X
P407
P577
2007-02-23T00:00:00Z